Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Radiopharm Forms Collaboration to Develop PD-L1 Diagnostic/Therapeutic Antibody

publication date: Aug 4, 2022

Australia’s Radiopharm Theranostics will collaborate with Lantheus, a Boston diagnostic company, to develop a PD-L1 nanobody that is a diagnostic and a therapy. NM-01 is made using genetically engineered camelid-derived single domain antibodies, that can be labelled with low-dose radioisotopes as a diagnostic and with higher radioisotope doses to treat multiple tumor types. Radiopharm has global rights to NM-01 as a therapy from NanoMab of the UK, which developed the therapy, and it will have China rights to the diagnostic from Lantheus. F.inancial details of the agreement were not disclosed. More details....

Stock Symbol: (ASX: RAD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China